Serendo Therapeutics is a biotechnology company dedicated to developing innovative treatments based on groundbreaking research in cellular and immune system regulation. Our work focuses on harnessing the potential of Endophilin A2 (EA2) to create novel therapeutics that address critical unmet medical needs.
By combining cutting-edge science with a patient-first approach, we strive to transform the future for those suffering from chronic inflammatory diseases. Our mission is to advance breakthrough therapies that improve lives and redefine treatment possibilities.
Follow us for insights into our research, partnerships, and advancements in immunology-driven therapies.
Company Details
- Founded
- -
- Address
- Critical Unmet Medical Needs.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.serendotx.com
- Keywords
- Damgaard Company.
Serendo Therapeutics Ab Questions
Serendo Therapeutics Ab's website is http://www.serendotx.com
Serendo Therapeutics Ab's LinkedIn profile is https://www.linkedin.com/company/serendo-therapeutics-ab
Serendo Therapeutics Ab's industry is
Biotechnology Research
Serendo Therapeutics Ab's top competitors are
10xhealth,
Unipile,
Omnio Ab,
Glomero,
2n Pharma,
Aukera Therapeutics,
Scandion Oncology,
Damgaard Company,
Wealth Fund Partners,
Topmd.
Serendo Therapeutics Ab's categories are Biotechnology Research
Serendo Therapeutics Ab's founding year is 2025
